Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca To Reclaim Full Rights To Several Drugs From Merck For $647M

This article was originally published in The Pink Sheet Daily

Executive Summary

By exercising its option, AstraZeneca also positions itself to regain full rights to Nexium and Prilosec as early as 2012.

You may also be interested in...



Merck/AstraZeneca Stay Tied To Each Other For Another Two Years

Merck and AstraZeneca continue a 30-year partnership after coming to terms that could benefit both companies.

AstraZeneca Collaboration With Medical Research Council May Mean New Life For 22 Compounds

U.K.-based academic research teams will be able to apply to work with the AstraZeneca compounds free of charge and receive grant funding from MRC under the collaboration.

AstraZeneca Pares R&D Areas By 25 Percent, But Will Continue Licensing

Following through on its R&D reduction pledge, AstraZeneca is calling off its own discovery efforts in 10 specific disease areas, though the company insists it will continue to pursue in-licensing deals in these therapeutic areas

Related Content

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel